Advertisement

Annals of Hematology

, Volume 97, Issue 7, pp 1297–1298 | Cite as

Histological transformation of MALT lymphoma to plasma cell leukemia after rituximab-containing therapy

  • Yutaro Suzuki
  • Akira Honda
  • Kumi Nakazaki
  • Hideaki Mizuno
  • Masako Ikemura
  • Aya Shinozaki-Ushiku
  • Fumihiko Nakamura
  • Masashi Fukayama
  • Mineo Kurokawa
Letter to the Editor

Dear Editor,

Mucosa-associated lymphoid tissue (MALT) lymphoma is a relatively common lymphoma that belongs to the group of marginal zone B cell lymphoma. Approximately 30% of MALT lymphomas show plasmacytic differentiation (PCD) on histological evaluation, and PCD is predominantly found in extragastric MALT lymphoma [1, 2]. We herein report a case of extragastric MALT lymphoma accompanied by secondary plasma cell leukemia (PCL) after rituximab-containing chemotherapy.

The case was a 73-year-old Japanese woman with relapsed and refractory small intestinal MALT lymphoma. Her initial onset was previously reported in detail [ 3]. At diagnosis, endoscopic examinations showed erosions extending from the jejunum to ileum. Histological evaluation revealed PCD and lambda light chain restriction (Fig. 1a). Four cycles of rituximab monotherapy and subsequent six cycles of rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisolone therapy led to partial response. Ten months later, a...

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Written informed consent was obtained from the patient.

References

  1. 1.
    Wöhrer S, Troch M, Streubel B, Hoffmann M, Müllauer L, Chott A et al (2007) Pathology and clinical course of MALT lymphoma with plasmacytic differentiation. Ann Oncol 18(12):2020–2024CrossRefPubMedGoogle Scholar
  2. 2.
    Cohen SM, Petryk M, Varma M, Kozuch PS, Ames ED, Grossbard ML (2006) Non-Hodgkin’s lymphoma of mucosa-associated lymphoid tissue. Lymphoma Oncol Oncol 1111:1100–1117Google Scholar
  3. 3.
    Tsukamoto A, Nakamura F, Nannya Y, Kobayashi Y, Shibahara J, Ichikawa M, Fukayama M, Koike K, Kurokawa M (2014) MALT lymphoma of the small bowel with protein-losing enteropathy. Int J Hematol 99:198–201CrossRefPubMedGoogle Scholar
  4. 4.
    Nakamura F, Nakamura F, Ikemura M, Fukayama M, Kurokawa M (2016) Extraosseous plasmacytoma in the nasal cavity after rituximab therapy against pulmonary MALT lymphoma. Ann Hematol 95:1733–1735CrossRefPubMedGoogle Scholar
  5. 5.
    Woehrer S, Streubel B, Chott A, Hoffmann M, Raderer M (2005) Transformation of MALT lymphoma to pure plasma cell histology following treatment with the anti-CD20 antibody rituximab. Leuk Lymphoma 46(11):1645–1649CrossRefPubMedGoogle Scholar
  6. 6.
    Klein N, Elis A, Radnay J, Zemer R, Klein A, Lishner M (2009) Transformation of MALT lymphoma to pure plasma cell histology: possible association with anti-CD20 antibody treatment. Isr Med Assoc J 11:703–704PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Yutaro Suzuki
    • 1
  • Akira Honda
    • 1
  • Kumi Nakazaki
    • 1
  • Hideaki Mizuno
    • 1
  • Masako Ikemura
    • 2
  • Aya Shinozaki-Ushiku
    • 2
  • Fumihiko Nakamura
    • 1
  • Masashi Fukayama
    • 2
  • Mineo Kurokawa
    • 1
  1. 1.Department of Hematology and Oncology, Graduate School of MedicineThe University of TokyoTokyoJapan
  2. 2.Department of Pathology, Graduate School of MedicineThe University of TokyoTokyoJapan

Personalised recommendations